• Home
  •  > 
  • Products

Products

OneTouch® Verio® Glucose Test

OneTouch® Verio® is the first blood glucose product launched by LifeScan that uses the innovative opposing electrode technology developed by Universal Biosensors.  LifeScan, a Johnson & Johnson company, first introduced OneTouch® Verio® to the market in January 2010 and it is now available globally. OneTouch® Verio® has been positively received by the market based on key competitive advantages that stem directly from the novel electrochemical approach. The OneTouch® Verio® represents world-class technology that utilises highly automated, state of the art manufacturing system developed by Universal Biosensors.

Key advantages of the technology in OneTouch® Verio®

  • Enables instant, (within seconds) readings of blood glucose levels.
  • Requires no calibration and uses a tiny finger prick blood sample (less than 0.5 µL).
  • The result is unaffected by the presence of unrelated sugars such as maltose and galactose which interfere with the results in a number of other blood glucose systems.

Glucose Monitoring

Point-of-care blood tests for blood glucose first appeared in the market in the late 1980s. These simple test devices allowed patients to take control of their insulin medication and led to dramatic advances in life expectancy and quality of life for diabetics. Today it is estimated that around 17 billion disposable sensor strips using electrochemical cells are used by diabetics each year. This remains the largest market in the point-of-care segment and has been valued at more than US$9.8 billion globally and continues to grow.

In Australia, the OneTouch® Verio® can be found at www.onetouch.com.au

Xprecia StrideTM Coagulation Analyzer

Following on from its successful validation with glucose, UBI has adapted its electrochemical cell to measure Prothrombin Time (PT/INR), a test used to monitor the anticoagulant therapy warfarin. The test is used to maintain patients on a safe and effective dose. If patients are taking too much warfarin they are at risk of serious bleeding events and if too little they are at risk of thrombosis. 

UBI has signed a long term supply and manufacturing agreement with Siemens Healthcare Diagnostics to manufacture three test strips for the professional point-of-care coagulation testing market.  The first product, a PT/INR test, was launched in December 2014.  UBI is also developing its own PT/INR device for use in decentralised settings including the patient self-test market.

Read more about PT/INR

Product Pipeline

With UBI's test strip technology now demonstrated in blood glucose, and coagulation testing the company is focused on adding new clinically relevant and commercially attractive tests to its product pipeline.

UBI is developing an immunoassay-based system (an important technique for biomarker measurement), which is progressing through the feasibility stage of the company's R&D pipeline.  Another key opportunity is UBI's early but exciting research into molecular diagnostics testing.

Read more about Immunoassay